The BRIM8 study (NCT01667419) evaluated the effects of BRAF inhibitor vemurafenib monotherapy in patients with resected, BRAFV600-mutant melanomas and found that 1 year of vemurafenib was well tolerated but may not be an optimal treatment regimen [92]. Here, BRAF is linked to melanoma.